BCL2 and acute myeloid leukemia: Its mechanistic versatility contrasts with yet complements targeted agents like venetoclax—a clinically validated BCL-2 inhibitor that achieved therapeutic efficacy in acute myeloid leukemia (AML) through selective apoptotic induction.